Of note, the use of CDK4/6 inhibitors in combination with mitogen-activated extracellular signal-regulated kinase (MEK), or mammalian target of rapamycin (mTOR) inhibitors for treating lung cancer are being tested in clinical trials (NCT03170206, NCT02857270). This evidence concerns the gene MTOR and lung carcinoma.